NCT07309094Recruiting
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD
Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
Chronic kidney disease (CKD) is the progressive damage to kidney function, associated with an increased risk of cardiovascular diseases, such as stroke or myocardial infarct, particularly in the most severe stages of CKD, in which the patient requires dialysis. Several risk factors are reported for CKD, such as diabetes mellitus, obesity and hypertension. One of the most increasingly recognized risk factors is the fat tissue malfunction, known as adiposopathy. The accumulation of fat tissue around the organs in conditions of obesity or diabetes accelerates the production of pro-inflammatory factors that may worsen the kidney and heart damage. New antidiabetic medications, such as glucagon-like peptide-1 receptor agonists (GLP-1RA), have proven beneficial effects on the kidney and heart due to several mechanisms, including anti-inflammatory actions and a potential action on the fat tissue. The aim of this study is to assess the link between adiposopathy and CKD, by investigating the changes in adiposopathy measures throughout treatment with GLP-1RA to a sample of patients with CKD.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 250 (estimated)
- First submitted
- 3 Dec 2025
- Start date
- Sept 2023
- Primary completion date
- Jul 2027
- Lead sponsor
- Cardenal Herrera University
- NCT number
- NCT07309094
What you commit to
- Study type: Observational
- Planned participants: 250
- From Sept 2023 to the primary completion date, Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- neuropsychiatric diseases preventing the patient from understanding the benefits/risks associated with the project
Age
- Age \<18 years
Other
- pregnancy
- CKD in stage G5 or G4 candidate for dialysis
- refusal to participate and/or consent revocation were considered as exclusion criteria
Who the study is looking for
- \> or = 18 years of age
- diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis
- had uncontrolled T2DM, CVDs and/or obesity
- willing to participate in the study and sign informed consent
Age in the registry: 18 years to 90 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vithas Valencia Consuelo Coordinator of this site? Confirm its status | Valencia | Spain | Recruiting |
Related publications
- The Effects of GLP-1RA-Based and SGLT2 Inhibitor Therapy on Perirenal Adipose Tissue in CKD Patients.Diabetes Obes Metab · 2026 · PMID 42865317
This page is information, not medical advice. Discuss any trial with your doctor.